IDEXX(US:IDXX) ZACKSยท2024-08-06 14:36Core Insights - Idexx Laboratories reported revenue of $1 billion for the quarter ended June 2024, reflecting a year-over-year increase of 6.4% and a slight revenue surprise of +0.11% over the Zacks Consensus Estimate [1] - The company's EPS was $2.44, down from $2.67 in the same quarter last year, resulting in an EPS surprise of -14.98% compared to the consensus estimate of $2.87 [1] Revenue Performance by Segment - Companion Animal Group - United States: Revenue was $628.68 million, slightly below the estimated $637.35 million, representing a year-over-year increase of +5.8% [3] - Companion Animal Group - International: Revenue reached $293.61 million, exceeding the estimated $282.88 million, with a year-over-year growth of +7.8% [4] - Livestock and Poultry Diagnostics (LPD) - International: Revenue was $25.19 million, surpassing the average estimate of $24.42 million, but showing a year-over-year decline of -1.2% [5] - Water - International: Revenue was $22.27 million, slightly below the estimated $22.92 million, with a year-over-year increase of +2% [6] - Companion Animal Group (CAG): Total revenue was $922.30 million, marginally below the estimated $923.58 million, reflecting a year-over-year increase of +6.4% [7] - Other Revenue: Revenue was $4.25 million, exceeding the average estimate of $4.07 million, with a year-over-year growth of +5.2% [8] - Livestock and Poultry Diagnostics (LPD): Revenue was $30.31 million, slightly above the estimated $29.98 million, with a year-over-year increase of +1.3% [9] - Water Revenue: Revenue was $46.73 million, surpassing the estimated $45.93 million, reflecting a year-over-year increase of +8.6% [9] - IDEXX VetLab Consumables: Revenue was $325.35 million, slightly above the estimated $324.54 million, with a year-over-year growth of +7.1% [10] - CAG Diagnostics Capital - Instruments: Revenue was $35.29 million, exceeding the average estimate of $34.87 million, with a year-over-year increase of +3.6% [11] - CAG - Reference Laboratory Diagnostic and Consulting Services: Revenue was $347.37 million, below the estimated $351.67 million, reflecting a year-over-year increase of +5.2% [12] - CAG - Rapid Assay Products: Revenue was $103.29 million, exceeding the estimated $100.59 million, with a year-over-year growth of +6.1% [13] Stock Performance - Idexx shares have returned -5.9% over the past month, compared to a -6.7% change in the Zacks S&P 500 composite, indicating potential underperformance in the near term [13]